DENDREON ANNOUNCES PROVENGE STUDY RESULTS

Dendreon announced that final results of its second Phase III study of Provenge, the company's investigational active immunotherapy for the treatment of advanced prostate cancer, will be presented at the ECCO 13 congress, Europe's preeminent cancer research conference, which begins Oct. 30 in Paris.

Provenge is designed to stimulate a patient's immune system against prostate cancer. It is developed through Dendreon's proprietary Antigen Delivery Cassette technology, which utilizes a recombinant form of an antigen found in 95 percent of prostate cancers, prostatic acid phosphatase.

Provenge is being further evaluated in an ongoing Phase III study in asymptomatic, metastatic androgen-independent prostate cancer under a special protocol assessment agreement with the FDA. The double-blind, placebo-controlled trial is enrolling men with advanced-stage prostate cancer at leading cancer centers around the country.